CN101780099A - 环磷腺苷葡胺组合药物 - Google Patents
环磷腺苷葡胺组合药物 Download PDFInfo
- Publication number
- CN101780099A CN101780099A CN 201010108233 CN201010108233A CN101780099A CN 101780099 A CN101780099 A CN 101780099A CN 201010108233 CN201010108233 CN 201010108233 CN 201010108233 A CN201010108233 A CN 201010108233A CN 101780099 A CN101780099 A CN 101780099A
- Authority
- CN
- China
- Prior art keywords
- composition
- medicine
- meglumine
- meglumine adenosine
- cycle phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 131
- HYMXALLEHXXORK-HTDNVCFESA-N (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 HYMXALLEHXXORK-HTDNVCFESA-N 0.000 title claims abstract description 16
- 239000002131 composite material Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 139
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 64
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 50
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 28
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 25
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 25
- 239000011718 vitamin C Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 160
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 80
- 229960005305 adenosine Drugs 0.000 claims description 80
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 79
- 229960003194 meglumine Drugs 0.000 claims description 79
- 229910019142 PO4 Inorganic materials 0.000 claims description 77
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 77
- 239000010452 phosphate Substances 0.000 claims description 77
- 239000000706 filtrate Substances 0.000 claims description 48
- 238000004108 freeze drying Methods 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 36
- 235000003969 glutathione Nutrition 0.000 claims description 27
- 229960003180 glutathione Drugs 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 24
- 238000000108 ultra-filtration Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 14
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- 229910000831 Steel Inorganic materials 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000003518 caustics Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 238000005374 membrane filtration Methods 0.000 claims description 12
- 239000010959 steel Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000020169 heat generation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 208000019804 backache Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011082 depyrogenation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 238000007539 photo-oxidation reaction Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229940090639 vitamin c combination Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-L meso-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-XIXRPRMCSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 238000010099 solid forming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
项目 | 心肌梗塞成活率% | 皮症率% | 发热率% | 疼痛率% |
注射用水对照组 | 0 | - | - | - |
硝酸甘油组 | 70 | 20 | - | |
现有技术环磷腺苷葡胺对照组 | 70 | 30 | 30 | 30 |
本发明实施例1组合药物 | 90 | 10 | 0 | 10 |
本发明实施例2组合药物 | 90 | 0 | 0 | 10 |
本发明实施例3组合药物 | 100 | 10 | 0 | 10 |
本发明实施例4组合药物 | 90 | 10 | 0 | 10 |
本发明实施例5组合药物 | 100 | 0 | 0 | 10 |
本发明实施例6组合药物 | 90 | 0 | 0 | 10 |
本发明实施例7组合药物 | 90 | 0 | 0 | 10 |
本发明实施例8组合药物 | 100 | 0 | 0 | 10 |
项目 | 心肌梗塞成活率% | 皮症率% | 发热率% | 疼痛率% |
本发明实施例9组合药物本发明实施例10组合药物 | 100100 | 00 | 00 | 1010 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101082335A CN101780099B (zh) | 2010-02-10 | 2010-02-10 | 环磷腺苷葡胺组合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101082335A CN101780099B (zh) | 2010-02-10 | 2010-02-10 | 环磷腺苷葡胺组合药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101780099A true CN101780099A (zh) | 2010-07-21 |
CN101780099B CN101780099B (zh) | 2012-01-04 |
Family
ID=42520324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101082335A Expired - Fee Related CN101780099B (zh) | 2010-02-10 | 2010-02-10 | 环磷腺苷葡胺组合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101780099B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107951846A (zh) * | 2017-12-06 | 2018-04-24 | 海南皇隆制药股份有限公司 | 一种注射用赖氨匹林冻干粉及其制备方法 |
CN107982220A (zh) * | 2017-12-06 | 2018-05-04 | 海南皇隆制药股份有限公司 | 一种防水解的注射用赖氨匹林组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027941A1 (en) * | 1997-12-01 | 1999-06-10 | Thione International, Inc. | Oral antioxidant preparation comprising selenium and reduced glutathione |
CN101181243A (zh) * | 2007-12-14 | 2008-05-21 | 广东宏远集团药业有限公司 | 一种环磷腺苷冻干制剂及其制备方法 |
CN101455631A (zh) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | 环磷腺苷葡胺注射液及其制备工艺 |
-
2010
- 2010-02-10 CN CN2010101082335A patent/CN101780099B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027941A1 (en) * | 1997-12-01 | 1999-06-10 | Thione International, Inc. | Oral antioxidant preparation comprising selenium and reduced glutathione |
CN101181243A (zh) * | 2007-12-14 | 2008-05-21 | 广东宏远集团药业有限公司 | 一种环磷腺苷冻干制剂及其制备方法 |
CN101455631A (zh) * | 2009-01-06 | 2009-06-17 | 湖北德康药业有限公司 | 环磷腺苷葡胺注射液及其制备工艺 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107951846A (zh) * | 2017-12-06 | 2018-04-24 | 海南皇隆制药股份有限公司 | 一种注射用赖氨匹林冻干粉及其制备方法 |
CN107982220A (zh) * | 2017-12-06 | 2018-05-04 | 海南皇隆制药股份有限公司 | 一种防水解的注射用赖氨匹林组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101780099B (zh) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102670497A (zh) | 一种稳定的s-奥拉西坦注射用制剂及其制备方法 | |
CN107789340A (zh) | 一种穿心莲雾化吸入用溶液制剂及其制备方法 | |
CN100382842C (zh) | 口服鹿瓜多肽组合物及其制备方法 | |
CN102068494B (zh) | 对化学性肝损伤有治疗作用的保健胶囊及其制备方法 | |
CN101020715A (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
CN101780099B (zh) | 环磷腺苷葡胺组合药物 | |
CN1729988A (zh) | 磷酸肌酸钠和镁盐的组合药物 | |
CN104511007A (zh) | 一种脑蛋白水解物的制备方法 | |
CN104706655A (zh) | 注射用环磷腺苷葡胺粉针剂药物组合物和制法 | |
CN109091500A (zh) | 一种小儿复方电解质葡萄糖注射液及其制备方法 | |
CN101829135A (zh) | 一种以胞磷胆碱钠和肌苷为活性成分的注射用制剂及其应用 | |
CN101926807A (zh) | 果糖组合药物 | |
CN105582546B (zh) | 一种恩替卡韦磷脂复合物和甘草酸二铵的复方肠溶片剂 | |
CN104511008A (zh) | 一种脑蛋白水解物制备方法 | |
CN101019869A (zh) | 前列地尔和穿琥宁/炎琥宁脂质体组合药物及其制备方法 | |
CN102008461B (zh) | 一种注射用布洛芬药物组合物 | |
CN102961397B (zh) | 一种脂肪乳注射液和复方氨基酸注射液的药物组合物 | |
CN100408047C (zh) | 果糖二磷酸钠和镁盐的组合药物 | |
CN104490802A (zh) | 红景天苷肠溶片及其制备方法 | |
CN102757471A (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN102614202A (zh) | 混合物以及注射用药液或者口服液 | |
CN101507723B (zh) | 一种治疗肺炎和上呼吸道感染的组合药物及其制备方法 | |
CN100490824C (zh) | 治疗血管类疾病的药物组合物、其制备方法及其用途 | |
CN101837011B (zh) | 治疗糖尿病的药物组合物 | |
CN1907293B (zh) | 一种治疗肺炎的组合药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Ocean University of China LAN Tai Pharmaceutical Co.,Ltd. Assignor: Deng Xuefeng Contract record no.: 2011530000027 Denomination of invention: Meglumine adenosine cyclophosphate composite medicament License type: Exclusive License Open date: 20100721 Record date: 20110615 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160205 Address after: 256100 Zibo Province, Yiyuan County, Yang Rui Road, No. 1, No. Patentee after: REYOUNG PHARMACEUTICAL Co.,Ltd. Address before: 334600 Jiangxi Lu Lin County of Guangfeng Province Road No. 156 Yongfeng Street Office Patentee before: Deng Xuefeng |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190211 Address after: 650000 Dianchi Golf Community G102, No. 6 Xingti Road, Xishan District, Kunming City, Yunnan Province Patentee after: Deng Xuefeng Address before: 256100 Ruiyang Road, Yiyuan County, Zibo City, Shandong Province Patentee before: REYOUNG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210113 Address after: No.6, Qimen Road, Shitai County, Chizhou City, Anhui Province 247000 Patentee after: ANHUI YANSHOUTANG PHARMACEUTICAL Co.,Ltd. Address before: 650000 Dianchi Golf Community G102, No. 6 Xingti Road, Xishan District, Kunming City, Yunnan Province Patentee before: Deng Xuefeng |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 |